How can biopharmaceutical companies streamline and accelerate biologics development? In this article, experts from Eurofins Optimed, Eurofins ADME Bioanalyses, and Eurofins BPT Biologics share how an integrated approach can support every stage of the journey, from manufacturing and bioanalysis to clinical development.
Written by Tanja Schubert, Isabelle Molina, Alicia Lacombe, Capucine Henquell and Arnaud Carlotti.
A UNIQUE INTEGRATED OFFER SUPPORTING BIOLOGICS DEVELOPMENT WITHIN EUROFINS
Tanja Schubert, National Business Line Leader Bioanalysis - Phase I Clinics France & BioPharma Product Testing France
Isabelle Molina, Head of Biologics and Biomarkers Eurofins ADME Bioanalyses
Alicia Lacombe, Head of Sales & Business Development Eurofins ADME Bioanalyses
Capucine Henquell, Business Manager Eurofins Optimed Clinical Research
Arnaud Carlotti, PhD, General Manager Eurofins BioPharma Product Testing Biologics
Eurofins offers a unique and fully integrated solution to support the development of biologics, including therapeutic antibodies such as ADCs, bispecific antibodies, recombinant proteins, conjugates, and emerging biotherapeutic formats.
Because these complex molecules require advanced characterization, robust bioanalysis, and strict GMP control throughout development and manufacturing, Eurofins combines the strengths of three complementary expert entities: Eurofins Optimed, Eurofins ADME Bioanalyses, and Eurofins BPT Biologics.
Together, they provide a seamless technical continuum from preclinical GLP studies through early and late-phase clinical development, while ensuring consistent, safe, and high-quality production of biologic drug batches.
Eurofins Optimed brings over 35 years of clinical trial expertise, with a state-of-the-art Phase I unit and a network of sites in Europe and the US. Their teams support sponsors across the full translational pathway, from protocol design to dose selection and escalation strategies. They are particularly experienced in first-in-human biologics, managing cold-chain requirements, specialised pharmacy preparation, and 24/7 medical oversight.
Eurofins ADME Bioanalyses offers industry-leading expertise in bioanalytical method development, therapeutic antibody quantification, pharmacokinetics, immunogenicity, and biomarker analysis. Using advanced platforms (ELISA, ECL, cell-based assays, LC-MS/MS, immunopurification, antibody characterisation), they provide highly sensitive, reliable data aligned with FDA, EMA, and ICH guidelines to support confident decision-making.
Eurofins BPT Biologics completes the service offering with comprehensive QC expertise for biomolecule manufacturing, from process development and optimisation to GMP or preclinical/clinical stage production. Continuous quality controls ensure batch reliability, reproducibility, and regulatory compliance, providing developers with well-characterised materials ready for analytical and regulatory evaluation.
By integrating manufacturing, bioanalysis, preclinical, and clinical capabilities, Eurofins minimises logistical risks, accelerates study initiation, improves scientific consistency, and simplifies project management through a single point of contact.
This cohesive, agile model provides a strategic advantage for biopharmaceutical companies seeking to efficiently and securely advance their biologic programmes towards success.
